• Je něco špatně v tomto záznamu ?

Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

L. Paz-Ares, MC. Garassino, Y. Chen, N. Reinmuth, K. Hotta, A. Poltoratskiy, D. Trukhin, MJ. Hochmair, M. Özgüroğlu, JH. Ji, G. Statsenko, N. Conev, I. Bondarenko, L. Havel, G. Losonczy, M. Xie, Z. Lai, N. Godin-Heymann, H. Mann, H. Jiang, Y....

. 2024 ; 30 (4) : 824-835. [pub] 20240216

Jazyk angličtina Země Spojené státy americké

Typ dokumentu randomizované kontrolované studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007115

PURPOSE: In the CASPIAN trial, first-line durvalumab plus platinum-etoposide (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small cell lung cancer (ES-SCLC). We report exploratory analyses of CASPIAN outcomes by programmed cell death ligand-1 (PD-L1) expression and tissue tumor mutational burden (tTMB). EXPERIMENTAL DESIGN: Patients were randomized (1:1:1) to durvalumab (1,500 mg) plus EP, durvalumab plus tremelimumab (75 mg) plus EP, or EP alone. Treatment effects in PD-L1 and tTMB subgroups were estimated using an unstratified Cox proportional hazards model. RESULTS: The PD-L1 and tTMB biomarker-evaluable populations (BEP) comprised 54.4% (438/805) and 35.2% (283/805) of the intention-to-treat population, respectively. PD-L1 prevalence was low: 5.7%, 25.8%, and 28.3% had PD-L1 expression on ≥1% tumor cells (TC), ≥1% immune cells (IC), and ≥1% TCs or ICs, respectively. OS benefit with durvalumab plus EP versus EP was similar across PD-L1 subgroups, with HRs all falling within the 95% confidence interval (CI) for the PD-L1 BEP (0.47‒0.79). OS benefit with durvalumab plus tremelimumab plus EP versus EP was greater in PD-L1 ≥1% versus <1% subgroups, although CIs overlapped. There was no evidence of an interaction between tTMB and treatment effect on OS (durvalumab plus EP vs. EP, P = 0.916; durvalumab plus tremelimumab plus EP vs. EP, P = 0.672). CONCLUSIONS: OS benefit with first-line durvalumab plus EP in patients with ES-SCLC was observed regardless of PD-L1 or tTMB status. PD-L1 expression may prove to be a useful biomarker for combined treatment with PD-(L)1 and CTLA-4 inhibition, although this requires confirmation with an independent dataset. See related commentary by Rolfo and Russo, p. 652.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007115
003      
CZ-PrNML
005      
20240423155730.0
007      
ta
008      
240412s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1158/1078-0432.CCR-23-1689 $2 doi
035    __
$a (PubMed)37801329
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Paz-Ares, Luis $u Department of Medical Oncology, Hospital Universitario 12 de Octubre, Lung Cancer Unit CNIO-H120, Complutense University and Ciberonc, Madrid, Spain $1 https://orcid.org/0000000219473364
245    10
$a Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden / $c L. Paz-Ares, MC. Garassino, Y. Chen, N. Reinmuth, K. Hotta, A. Poltoratskiy, D. Trukhin, MJ. Hochmair, M. Özgüroğlu, JH. Ji, G. Statsenko, N. Conev, I. Bondarenko, L. Havel, G. Losonczy, M. Xie, Z. Lai, N. Godin-Heymann, H. Mann, H. Jiang, Y. Shrestha, JW. Goldman
520    9_
$a PURPOSE: In the CASPIAN trial, first-line durvalumab plus platinum-etoposide (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small cell lung cancer (ES-SCLC). We report exploratory analyses of CASPIAN outcomes by programmed cell death ligand-1 (PD-L1) expression and tissue tumor mutational burden (tTMB). EXPERIMENTAL DESIGN: Patients were randomized (1:1:1) to durvalumab (1,500 mg) plus EP, durvalumab plus tremelimumab (75 mg) plus EP, or EP alone. Treatment effects in PD-L1 and tTMB subgroups were estimated using an unstratified Cox proportional hazards model. RESULTS: The PD-L1 and tTMB biomarker-evaluable populations (BEP) comprised 54.4% (438/805) and 35.2% (283/805) of the intention-to-treat population, respectively. PD-L1 prevalence was low: 5.7%, 25.8%, and 28.3% had PD-L1 expression on ≥1% tumor cells (TC), ≥1% immune cells (IC), and ≥1% TCs or ICs, respectively. OS benefit with durvalumab plus EP versus EP was similar across PD-L1 subgroups, with HRs all falling within the 95% confidence interval (CI) for the PD-L1 BEP (0.47‒0.79). OS benefit with durvalumab plus tremelimumab plus EP versus EP was greater in PD-L1 ≥1% versus <1% subgroups, although CIs overlapped. There was no evidence of an interaction between tTMB and treatment effect on OS (durvalumab plus EP vs. EP, P = 0.916; durvalumab plus tremelimumab plus EP vs. EP, P = 0.672). CONCLUSIONS: OS benefit with first-line durvalumab plus EP in patients with ES-SCLC was observed regardless of PD-L1 or tTMB status. PD-L1 expression may prove to be a useful biomarker for combined treatment with PD-(L)1 and CTLA-4 inhibition, although this requires confirmation with an independent dataset. See related commentary by Rolfo and Russo, p. 652.
650    _2
$a lidé $7 D006801
650    12
$a malobuněčný karcinom plic $x farmakoterapie $x genetika $7 D055752
650    _2
$a antigeny CD274 $x genetika $7 D060890
650    _2
$a etoposid $7 D005047
650    _2
$a platina $7 D010984
650    12
$a nádory plic $x farmakoterapie $x genetika $7 D008175
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
650    12
$a monoklonální protilátky $7 D000911
650    12
$a humanizované monoklonální protilátky $7 D061067
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Garassino, Marina Chiara $u Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy $u Department of Medicine, Section of Hematology/Oncology, Thoracic Oncology Unit, University of Chicago, Chicago, Illinois $1 https://orcid.org/0000000238215598 $7 xx0280337
700    1_
$a Chen, Yuanbin $u Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan $1 https://orcid.org/0009000641758055
700    1_
$a Reinmuth, Niels $u Asklepios Lung Clinic, Member of the German Center for Lung Research (DZL), Munich-Gauting, Germany $1 https://orcid.org/0000000273694512
700    1_
$a Hotta, Katsuyuki $u Okayama University Hospital, Okayama, Japan $1 https://orcid.org/0000000201120843
700    1_
$a Poltoratskiy, Artem $u Petrov Research Institute of Oncology, St. Petersburg, Russian Federation $1 https://orcid.org/0000000332592242
700    1_
$a Trukhin, Dmytro $u Odessa Regional Oncological Dispensary, Odessa, Ukraine $1 https://orcid.org/0009000634120758
700    1_
$a Hochmair, Maximilian J $u Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria $1 https://orcid.org/0000000286732450
700    1_
$a Özgüroğlu, Mustafa $u Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey $1 https://orcid.org/0000000284178628
700    1_
$a Ji, Jun Ho $u Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of South Korea $1 https://orcid.org/0000000317302606
700    1_
$a Statsenko, Galina $u Omsk Regional Cancer Center, Omsk, Russian Federation $1 https://orcid.org/0000000171238639
700    1_
$a Conev, Nikolay $u Clinic of Medical Oncology, UMHAT St Marina, Varna, Bulgaria $1 https://orcid.org/0000000152670354
700    1_
$a Bondarenko, Igor $u Dnipropetrovsk Medical Academy, Dnipro, Ukraine $1 https://orcid.org/0000000270712471
700    1_
$a Havel, Libor $u Thomayer Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/000900079131226X
700    1_
$a Losonczy, György $u Semmelweis University, Budapest, Hungary $1 https://orcid.org/0000000202115237
700    1_
$a Xie, Mingchao $u AstraZeneca, Waltham, Massachusetts $1 https://orcid.org/0009000670615483
700    1_
$a Lai, Zhongwu $u AstraZeneca, Gaithersburg, Maryland $1 https://orcid.org/0000000215068222
700    1_
$a Godin-Heymann, Nadia $u AstraZeneca, Cambridge, United Kingdom $1 https://orcid.org/0000000332600302
700    1_
$a Mann, Helen $u AstraZeneca, Cambridge, United Kingdom $1 https://orcid.org/0000000194262332
700    1_
$a Jiang, Haiyi $u AstraZeneca, Gaithersburg, Maryland $1 https://orcid.org/0009000286776821
700    1_
$a Shrestha, Yashaswi $u AstraZeneca, Gaithersburg, Maryland $1 https://orcid.org/0000000255670277
700    1_
$a Goldman, Jonathan W $u David Geffen School of Medicine at UCLA, Los Angeles, California $1 https://orcid.org/0000000249258243
773    0_
$w MED00001121 $t Clinical cancer research $x 1557-3265 $g Roč. 30, č. 4 (2024), s. 824-835
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37801329 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155726 $b ABA008
999    __
$a ok $b bmc $g 2081233 $s 1216882
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 30 $c 4 $d 824-835 $e 20240216 $i 1557-3265 $m Clinical cancer research $n Clin Cancer Res $x MED00001121
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace